ReviewChemical & biomedical imaging2025
Aptamers as a New Frontier in Molecular Cancer Imaging Technologies.
Review in Chemical & biomedical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Development of a graphene oxide-based PEGylated fluorescent aptasensor with ultrahigh-sensitivity and anti-fouling properties for the detection of serum carcinoembryonic antigen levels.Mikrochimica acta · 2026Article
- Orthogonal functionalization of lithium niobate nanoparticles with targeting aptamers and caged chemotherapeutics.RSC applied interfaces · 2026Article
- Dynamic Monitoring of Content Variation of Guanosine Triphosphate in Single Cells under External Stimulus with Functionalized Fluorescent/Photothermal NbChemical & biomedical imaging · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Molecular imaging has emerged as a transformative tool in cancer diagnosis, enabling the visualization of biological processes at the cellular and molecular levels. Aptamers, single-stranded oligonucleotides with high affinity and specificity for target molecules, have gained significant attention as versatile probes for molecular imaging due to their unique properties, including small size, ease of modification, low immunogenicity, and rapid tissue penetration. This review explores the integration of aptamers with various imaging agents to enhance cancer diagnosis and therapy. Aptamer-based imaging probes offer high sensitivity and real-time visualization of tumor markers. Aptamer-based fluorescence probes and aptamer-conjugated magnetic resonance imaging (MRI) probes, including gadolinium-based contrast agents, improve tumor targeting and imaging resolution. Additionally, aptamers have been utilized in single-photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging to enhance the specificity of radiotracers for cancer detection. Furthermore, aptamer-targeted ultrasound and computed tomography (CT) imaging demonstrate the potential for noninvasive and precise tumor localization. By leveraging the unique advantages of aptamers, these imaging strategies not only improve diagnostic accuracy but also pave the way for image-guided cancer therapies. This review highlights the significant role of aptamers in advancing molecular imaging and their potential to revolutionize cancer diagnosis and treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.